Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for ANAB

Stock Name	AnaptysBio Inc
Ticker	ANAB(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0327241065
LEI	529900HH4WQT03IG1A12

Show aggregate ANAB holdings

News associated with ANAB

AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $45.00 price target on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 127.16% from the company’s current price. Several other […] - 2025-09-18 02:24:44
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.13: Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy […] - 2025-09-16 02:46:48
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.13 Average Target Price from Analysts: Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to […] - 2025-08-22 03:12:54
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group: UBS Group restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock, up from their prior price target of $18.00. A number of other research analysts have also […] - 2025-08-13 04:26:45
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB): Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 24.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,062 shares of the biotechnology company’s stock after selling 660 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in […] - 2025-08-11 05:32:56
Federated Hermes Inc. Has $154,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB): Federated Hermes Inc. lowered its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,274 shares of the biotechnology company’s stock after selling 36,910 shares during the quarter. Federated Hermes Inc.’s holdings […] - 2025-08-11 04:48:58
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The […] - 2025-07-30 04:24:54
Alps Advisors Inc. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB): Alps Advisors Inc. trimmed its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,126 shares of the biotechnology company’s stock after selling 1,478 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:26:00
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $42.38: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-07-03 02:41:00
AnaptysBio (NASDAQ:ANAB) Upgraded at HC Wainwright: AnaptysBio (NASDAQ:ANAB – Get Free Report) was upgraded by research analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, MarketBeat.com reports. The firm currently has a $38.00 price objective on the biotechnology company’s stock, up from their previous price objective of $22.00. HC Wainwright’s […] - 2025-06-06 02:58:51
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Squarepoint Ops LLC: Squarepoint Ops LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 80,870 shares of the biotechnology company’s stock after purchasing an additional 36,365 shares during the period. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $1,071,000 as of its most recent filing […] - 2025-06-01 05:29:02
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $90.00 target price on the biotechnology company’s stock, up from their previous target price of $54.00. Guggenheim’s price objective points to a […] - 2025-05-30 03:08:51
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $52.00 to $54.00. The stock had previously closed at $20.13, but opened at $21.14. Guggenheim currently has a buy rating on the stock. AnaptysBio shares last traded at $22.10, […] - 2025-05-30 02:27:21
D. E. Shaw & Co. Inc. Reduces Stake in AnaptysBio, Inc. (NASDAQ:ANAB): D. E. Shaw & Co. Inc. trimmed its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 197,107 shares of the biotechnology company’s stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc.’s holdings in AnaptysBio were worth $2,610,000 as […] - 2025-05-20 04:57:05
18,954 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Bought by Graham Capital Management L.P.: Graham Capital Management L.P. bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 18,954 shares of the biotechnology company’s stock, valued at approximately $251,000. Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased […] - 2025-05-19 05:26:52
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.88: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-05-14 02:34:53
Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB): Barclays PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,567 shares of the biotechnology company’s stock after acquiring an additional 39,267 shares during the […] - 2025-05-05 05:26:54
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.: Federated Hermes Inc. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 85.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,184 shares of the biotechnology company’s stock after selling 272,059 shares during the quarter. Federated […] - 2025-04-17 05:18:48
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Vanguard Group Inc.: Vanguard Group Inc. lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after purchasing an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of AnaptysBio worth $24,411,000 as […] - 2025-04-16 04:22:49
Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO): AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Risk & Volatility AnaptysBio has a beta of […] - 2025-03-25 03:56:46
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.11: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-25 03:52:42
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 at JPMorgan Chase & Co.: AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $36.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 156.10% from the […] - 2025-03-07 04:10:52
AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 31.34% from the company’s previous close. Several […] - 2025-03-06 06:31:49
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-02-28 04:26:55
Jennison Associates LLC Boosts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB): Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,131 shares of the biotechnology company’s stock after acquiring an additional 4,242 shares during the […] - 2025-02-07 07:55:30
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB): AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush […] - 2025-02-06 04:36:55
Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB): Wolfe Research assumed coverage on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock. Several other research firms also recently commented on ANAB. Guggenheim cut their target price on […] - 2025-02-05 07:10:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ANAB holdings

Date	Number of ANAB Shares Held	Base Market Value of ANAB Shares	Local Market Value of ANAB Shares	Change in ANAB Shares Held	Change in ANAB Base Value	Current Price per ANAB Share Held	Previous Price per ANAB Share Held
2025-11-11 (Tuesday)	17,976	USD 603,275	USD 603,275	0	USD -7,549	USD 33.56	USD 33.98
2025-11-10 (Monday)	17,976	USD 610,824	USD 610,824	46	USD -100,101	USD 33.98	USD 39.65
2025-11-07 (Friday)	17,930	USD 710,925	USD 710,925	0	USD 25,999	USD 39.65	USD 38.2
2025-11-06 (Thursday)	17,930	USD 684,926	USD 684,926	46	USD 41,102	USD 38.2	USD 36
2025-11-05 (Wednesday)	17,884	USD 643,824	USD 643,824	0	USD 22,534	USD 36	USD 34.74
2025-11-04 (Tuesday)	17,884	USD 621,290	USD 621,290	46	USD -21,592	USD 34.74	USD 36.04
2025-11-03 (Monday)	17,838	USD 642,882	USD 642,882	0	USD -9,632	USD 36.04	USD 36.58
2025-10-31 (Friday)	17,838	USD 652,514	USD 652,514	0	USD 1,962	USD 36.58	USD 36.47
2025-10-30 (Thursday)	17,838	USD 650,552	USD 650,552	230	USD 14,551	USD 36.47	USD 36.12
2025-10-29 (Wednesday)	17,608	USD 636,001	USD 636,001	92	USD 2,622	USD 36.12	USD 36.16
2025-10-28 (Tuesday)	17,516	USD 633,379	USD 633,379	0	USD -350	USD 36.16	USD 36.18
2025-10-27 (Monday)	17,516	USD 633,729	USD 633,729	0	USD 19,443	USD 36.18	USD 35.07

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ANAB by Blackrock for IE00BDZVHG35

Show aggregate share trades of ANAB

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 46 35.680 30.270 30.811 USD 1,417 22.52
2025-11-06 BUY 46 40.960 35.910 36.415 USD 1,675 22.35
2025-11-04 BUY 46 36.500 34.595 34.786 USD 1,600 22.21
2025-10-30 BUY 230 37.800 36.050 36.225 USD 8,332 21.97
2025-10-29 BUY 92 36.120 38.380 38.154 USD 3,510 21.89
2025-10-22 SELL -184 33.650 34.810 34.694 USD -6,384 21.52 Loss of -2,424 on sale
2025-10-20 BUY 92 35.280 35.577 35.547 USD 3,270 21.37
2025-10-17 BUY 230 34.630 35.400 35.323 USD 8,124 21.29
2025-10-15 BUY 368 34.290 34.415 34.403 USD 12,660 21.22
2025-10-03 BUY 322 30.940 32.240 32.110 USD 10,339 21.10
2025-10-02 BUY 46 31.340 32.150 32.069 USD 1,475 21.04
2025-10-01 BUY 94 31.970 33.480 33.329 USD 3,133 20.97
2025-09-26 BUY 94 23.580 23.990 23.949 USD 2,251 20.88
2025-09-25 BUY 94 22.040 22.520 22.472 USD 2,112 20.88
2025-09-18 BUY 53 21.080 21.225 21.211 USD 1,124 20.88
2025-09-17 BUY 159 19.810 20.400 20.341 USD 3,234 20.88
2025-09-11 SELL -52 23.200 23.635 23.592 USD -1,227 20.88 Loss of -141 on sale
2025-09-10 BUY 104 22.780 22.800 22.798 USD 2,371 20.87
2025-07-17 SELL -102 26.680 27.465 27.387 USD -2,793 20.75 Loss of -677 on sale
2025-07-11 SELL -416 26.200 26.700 26.650 USD -11,086 20.60 Loss of -2,518 on sale
2025-07-02 BUY 2,860 23.880 24.690 24.609 USD 70,382 20.48
2025-06-25 BUY 104 23.240 23.590 23.555 USD 2,450 20.42
2025-06-11 BUY 104 23.600 24.370 24.293 USD 2,526 20.19
2025-06-10 BUY 104 23.970 24.290 24.258 USD 2,523 20.16
2025-06-04 SELL -52 21.270 24.680 24.339 USD -1,266 20.09 Loss of -221 on sale
2025-04-23 BUY 52 20.420 22.290 22.103 USD 1,149 19.87
2025-04-10 SELL -416 16.240 16.590 16.555 USD -6,887 19.95 Profit of 1,411 on sale
2025-04-08 SELL -52 16.980 18.694 18.523 USD -963 20.02 Profit of 78 on sale
2025-04-07 SELL -52 17.780 18.740 18.644 USD -969 20.04 Profit of 73 on sale
2025-04-04 SELL -260 18.510 19.360 19.275 USD -5,012 20.06 Profit of 204 on sale
2025-04-01 BUY 212 18.400 18.650 18.625 USD 3,948 20.09
2025-03-31 SELL -159 18.590 18.805 18.784 USD -2,987 20.11 Profit of 211 on sale
2025-03-21 BUY 1,443 17.080 18.210 18.097 USD 26,114 20.25
2025-03-14 SELL -784 16.730 17.730 17.630 USD -13,822 20.50 Profit of 2,254 on sale
2025-03-07 SELL -98 16.340 17.205 17.118 USD -1,678 20.77 Profit of 358 on sale
2025-03-04 SELL -49 15.250 15.590 15.556 USD -762 20.99 Profit of 266 on sale
2025-02-25 BUY 98 17.190 17.600 17.559 USD 1,721 21.38
2025-02-19 SELL -48 19.610 20.500 20.411 USD -980 21.59 Profit of 57 on sale
2025-02-13 BUY 193 19.290 19.360 19.353 USD 3,735 21.69
2025-02-11 BUY 196 12.375 12.990 12.928 USD 2,534 22.00
2024-12-30 SELL -1,838 13.220 13.340 13.328 USD -24,497 24.69 Profit of 20,878 on sale
2024-11-18 SELL -783 18.880 19.240 19.204 USD -15,037 26.41 Profit of 5,646 on sale
2024-11-08 SELL -52 21.310 21.805 21.756 USD -1,131 27.13 Profit of 279 on sale
2024-10-21 SELL -52 35.370 35.705 35.672 USD -1,855 0.00 Loss of -1,855 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	46	35.680	30.270	30.811	USD 1,417	22.52
2025-11-06	BUY	46	40.960	35.910	36.415	USD 1,675	22.35
2025-11-04	BUY	46	36.500	34.595	34.786	USD 1,600	22.21
2025-10-30	BUY	230	37.800	36.050	36.225	USD 8,332	21.97
2025-10-29	BUY	92	36.120	38.380	38.154	USD 3,510	21.89
2025-10-22	SELL	-184	33.650	34.810	34.694	USD -6,384	21.52 Loss of -2,424 on sale
2025-10-20	BUY	92	35.280	35.577	35.547	USD 3,270	21.37
2025-10-17	BUY	230	34.630	35.400	35.323	USD 8,124	21.29
2025-10-15	BUY	368	34.290	34.415	34.403	USD 12,660	21.22
2025-10-03	BUY	322	30.940	32.240	32.110	USD 10,339	21.10
2025-10-02	BUY	46	31.340	32.150	32.069	USD 1,475	21.04
2025-10-01	BUY	94	31.970	33.480	33.329	USD 3,133	20.97
2025-09-26	BUY	94	23.580	23.990	23.949	USD 2,251	20.88
2025-09-25	BUY	94	22.040	22.520	22.472	USD 2,112	20.88
2025-09-18	BUY	53	21.080	21.225	21.211	USD 1,124	20.88
2025-09-17	BUY	159	19.810	20.400	20.341	USD 3,234	20.88
2025-09-11	SELL	-52	23.200	23.635	23.592	USD -1,227	20.88 Loss of -141 on sale
2025-09-10	BUY	104	22.780	22.800	22.798	USD 2,371	20.87
2025-07-17	SELL	-102	26.680	27.465	27.387	USD -2,793	20.75 Loss of -677 on sale
2025-07-11	SELL	-416	26.200	26.700	26.650	USD -11,086	20.60 Loss of -2,518 on sale
2025-07-02	BUY	2,860	23.880	24.690	24.609	USD 70,382	20.48
2025-06-25	BUY	104	23.240	23.590	23.555	USD 2,450	20.42
2025-06-11	BUY	104	23.600	24.370	24.293	USD 2,526	20.19
2025-06-10	BUY	104	23.970	24.290	24.258	USD 2,523	20.16
2025-06-04	SELL	-52	21.270	24.680	24.339	USD -1,266	20.09 Loss of -221 on sale
2025-04-23	BUY	52	20.420	22.290	22.103	USD 1,149	19.87
2025-04-10	SELL	-416	16.240	16.590	16.555	USD -6,887	19.95 Profit of 1,411 on sale
2025-04-08	SELL	-52	16.980	18.694	18.523	USD -963	20.02 Profit of 78 on sale
2025-04-07	SELL	-52	17.780	18.740	18.644	USD -969	20.04 Profit of 73 on sale
2025-04-04	SELL	-260	18.510	19.360	19.275	USD -5,012	20.06 Profit of 204 on sale
2025-04-01	BUY	212	18.400	18.650	18.625	USD 3,948	20.09
2025-03-31	SELL	-159	18.590	18.805	18.784	USD -2,987	20.11 Profit of 211 on sale
2025-03-21	BUY	1,443	17.080	18.210	18.097	USD 26,114	20.25
2025-03-14	SELL	-784	16.730	17.730	17.630	USD -13,822	20.50 Profit of 2,254 on sale
2025-03-07	SELL	-98	16.340	17.205	17.118	USD -1,678	20.77 Profit of 358 on sale
2025-03-04	SELL	-49	15.250	15.590	15.556	USD -762	20.99 Profit of 266 on sale
2025-02-25	BUY	98	17.190	17.600	17.559	USD 1,721	21.38
2025-02-19	SELL	-48	19.610	20.500	20.411	USD -980	21.59 Profit of 57 on sale
2025-02-13	BUY	193	19.290	19.360	19.353	USD 3,735	21.69
2025-02-11	BUY	196	12.375	12.990	12.928	USD 2,534	22.00
2024-12-30	SELL	-1,838	13.220	13.340	13.328	USD -24,497	24.69 Profit of 20,878 on sale
2024-11-18	SELL	-783	18.880	19.240	19.204	USD -15,037	26.41 Profit of 5,646 on sale
2024-11-08	SELL	-52	21.310	21.805	21.756	USD -1,131	27.13 Profit of 279 on sale
2024-10-21	SELL	-52	35.370	35.705	35.672	USD -1,855	0.00 Loss of -1,855 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANAB

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	92,308	0	183,005	50.4%
2025-09-18	58,201	0	106,687	54.6%
2025-09-17	105,431	873	320,514	32.9%
2025-09-16	191,351	14,369	566,480	33.8%
2025-09-15	166,542	12,680	469,729	35.5%
2025-09-12	122,619	0	188,382	65.1%
2025-09-11	107,589	0	138,671	77.6%
2025-09-10	122,385	0	174,863	70.0%
2025-09-09	69,966	0	98,957	70.7%
2025-09-08	74,734	0	107,417	69.6%
2025-09-05	75,329	0	104,698	71.9%
2025-09-04	113,219	0	168,716	67.1%
2025-09-03	102,133	0	140,378	72.8%
2025-09-02	29,714	122	45,208	65.7%
2025-08-29	105,678	0	137,685	76.8%
2025-08-28	18,607	0	46,589	39.9%
2025-08-27	47,648	870	76,479	62.3%
2025-08-26	48,080	1,000	99,553	48.3%
2025-08-25	35,311	0	52,989	66.6%
2025-08-22	54,262	328	78,722	68.9%
2025-08-21	83,095	2,019	146,968	56.5%
2025-08-20	58,202	0	101,839	57.2%
2025-08-19	69,349	0	109,095	63.6%
2025-08-18	45,757	300	66,872	68.4%
2025-08-15	49,379	0	85,030	58.1%
2025-08-14	51,063	1	93,195	54.8%
2025-08-13	176,608	66	417,787	42.3%
2025-08-12	48,149	0	98,556	48.9%
2025-08-11	70,002	0	155,360	45.1%
2025-08-08	139,058	21,803	613,210	22.7%
2025-08-07	79,784	643	173,811	45.9%
2025-08-06	77,521	3	179,677	43.1%
2025-08-05	65,167	0	161,070	40.5%
2025-08-04	27,989	0	67,303	41.6%
2025-08-01	45,155	0	116,703	38.7%
2025-07-31	84,525	960	201,920	41.9%
2025-07-30	155,697	816	333,900	46.6%
2025-07-29	57,495	60	119,685	48.0%
2025-07-28	59,023	0	119,581	49.4%
2025-07-25	73,692	49	186,893	39.4%
2025-07-24	70,238	54	146,166	48.1%
2025-07-23	92,577	1,556	353,307	26.2%
2025-07-22	55,841	4,032	156,457	35.7%
2025-07-21	102,030	40	188,906	54.0%
2025-07-18	50,078	9	80,374	62.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE